Tahereh Ghaziani, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 7
Offices
7 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ghaziani’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C156903 · Current
Licensed to practise in California · since 2018 · expires 2028-07-31 · Shahid Beheshti University of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$95,382
Medicare paid this office $95,382 for 338 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 128 | $34,972 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $11,024 | $106 |
| Return visit (30+ min) | 60 | $7,674 | $116 |
| New patient visit (60+ min) | 38 | $7,541 | $198 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 24 | $6,864 | $202 |
See all 12 services
| Long return visit (40+ min) | 128 | $34,972 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $11,024 | $106 |
| Return visit (30+ min) | 60 | $7,674 | $116 |
| New patient visit (60+ min) | 38 | $7,541 | $198 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 24 | $6,864 | $202 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,478 | $154 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 31 | $2,918 | $91 |
| Long return visit (40+ min) | 17 | $2,585 | $129 |
| New patient visit (45+ min) | 15 | $2,217 | $148 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,964 | $103 |
| Short return visit (20+ min) | 11 | $879 | $80 |
| Measurement of liver stiffness | 21 | $178 | $8 |
Procedures Medicare counted
| Colonoscopy | 17 | More than 46% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 87 | More than 74% of doctors who do this |
Who their Medicare patients are
338 Original Medicare patients in 2024. Average age 71 · Under 65 16% · 85 and older 6% · Women 44% · Also on Medicaid 41% · Health risk score 2.84. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 46% · Chronic kidney disease 40% · Coronary heart disease 31% · Heart failure 23% · Atrial fibrillation 21% · Cancer 20% · Depression 20% · COPD 14% · Stroke 9% · Dementia 8%.
The office billed $589,926, Medicare allowed $121,928 and paid $95,382; for 708 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 338 | 708 | 71 | 2.84 | $589,926 | $95,382 |
| 2023 | 310 | 615 | 72 | 2.58 | $504,041 | $71,079 |
| 2022 | 220 | 446 | 71 | 2.63 | $391,997 | $54,768 |
| 2021 | 179 | 425 | 71 | 2.14 | $414,083 | $56,320 |
| 2020 | 124 | 284 | 69 | 2.41 | $199,245 | $29,697 |
| 2019 | 246 | 549 | 66 | 3.17 | $236,393 | $52,926 |
| 2018 | 294 | 889 | 65 | 3.12 | $328,570 | $83,714 |
| 2017 | 301 | 803 | 65 | 2.96 | $299,938 | $75,524 |
| 2016 | 257 | 729 | 64 | 2.89 | $285,370 | $68,395 |
| 2015 | 281 | 768 | 64 | 2.71 | $293,312 | $74,024 |
| 2014 | 198 | 464 | 64 | 2.59 | $144,566 | $36,481 |
| 2013 | 167 | 467 | 64 | 2.85 | $162,989 | $38,503 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Long return visit (40+ min) | 74 | $13,169 | $121 |
| Long return visit (40+ min) | 53 | $10,984 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $7,503 | $107 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 28 | $6,163 | $199 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,001 | $156 |
| New patient visit (60+ min) | 30 | $4,895 | $163 |
| New patient visit (60+ min) | 26 | $4,117 | $158 |
| Return visit (30+ min) | 29 | $2,572 | $80 |
| Return visit (30+ min) | 23 | $2,383 | $88 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,660 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,043 | $80 |
| Short return visit (20+ min) | 14 | $802 | $57 |
| Measurement of liver stiffness | 30 | $283 | $9 |
2022: 10 services
| Long return visit (40+ min) | 58 | $14,351 | $127 |
| Long return visit (40+ min) | 66 | $12,045 | $128 |
| New patient visit (60+ min) | 35 | $5,357 | $153 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 19 | $5,162 | $215 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,063 | $93 |
| New patient visit (60+ min) | 17 | $2,676 | $157 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,197 | $169 |
| Return visit (30+ min) | 20 | $1,636 | $74 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $939 | $72 |
| Measurement of liver stiffness | 16 | $153 | $10 |
2021: 9 services
| Long return visit (40+ min) | 71 | $14,449 | $128 |
| Long return visit (40+ min) | 45 | $12,458 | $134 |
| New patient visit (60+ min) | 44 | $7,375 | $168 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 17 | $5,369 | $224 |
| New patient visit (60+ min) | 28 | $5,071 | $181 |
| Return visit (30+ min) | 25 | $2,587 | $83 |
| New patient visit (45+ min) | 17 | $2,066 | $122 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,107 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,017 | $68 |
2020: 6 services
| Long return visit (40+ min) | 37 | $6,417 | $99 |
| Long return visit (40+ min) | 28 | $5,122 | $100 |
| New patient visit (60+ min) | 26 | $3,999 | $154 |
| New patient visit (60+ min) | 17 | $2,383 | $140 |
| Return visit (30+ min) | 14 | $1,365 | $72 |
| New patient visit (45+ min) | 11 | $1,187 | $108 |
2019: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $17,226 | $88 |
| Long return visit (40+ min) | 92 | $12,168 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,171 | $171 |
| Return visit (30+ min) | 37 | $2,202 | $56 |
| Long return visit (40+ min) | 20 | $2,125 | $92 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,740 | $102 |
2018: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 100 | $34,580 | $88 |
| Long return visit (40+ min) | 91 | $14,610 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $10,338 | $164 |
| Return visit (30+ min) | 62 | $4,640 | $60 |
| Long return visit (40+ min) | 17 | $2,287 | $95 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 22 | $2,211 | $100 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,112 | $101 |
| Biopsy of large bowel using a flexible endoscope | 12 | $1,515 | $117 |
| Short return visit (20+ min) | 14 | $440 | $28 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $73 | $5 |
2017: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $25,866 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,030 | $170 |
| Long return visit (40+ min) | 71 | $9,864 | $90 |
| Long return visit (40+ min) | 39 | $5,363 | $103 |
| Return visit (30+ min) | 62 | $4,930 | $59 |
| Return visit (30+ min) | 43 | $2,870 | $65 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 11 | $2,575 | $215 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | $2,472 | $99 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,529 | $109 |
| Short return visit (20+ min) | 13 | $513 | $37 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 13 | $61 | $4 |
2016: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $21,783 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 67 | $11,558 | $158 |
| Long return visit (40+ min) | 54 | $9,339 | $102 |
| Return visit (30+ min) | 62 | $6,176 | $76 |
| Return visit (30+ min) | 37 | $3,115 | $55 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 12 | $2,652 | $189 |
| Long return visit (40+ min) | 18 | $2,420 | $81 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,318 | $97 |
| Short return visit (20+ min) | 11 | $507 | $36 |
2015: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $23,653 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 79 | $15,884 | $164 |
| Return visit (30+ min) | 55 | $6,747 | $84 |
| Long return visit (40+ min) | 32 | $4,914 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,921 | $58 |
| Return visit (30+ min) | 36 | $2,758 | $56 |
| Long return visit (40+ min) | 18 | $1,975 | $90 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,649 | $110 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,232 | $82 |
| New patient visit (45+ min) | 14 | $1,231 | $88 |
| Drainage of fluid from abdominal cavity using imaging guidance | 11 | $1,190 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,112 | $101 |
| Short return visit (20+ min) | 15 | $682 | $38 |
2014: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $5,920 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,098 | $164 |
| Short return visit (20+ min) | 49 | $3,368 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,004 | $111 |
| Return visit (30+ min) | 33 | $2,852 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,112 | $84 |
| Long return visit (40+ min) | 15 | $1,982 | $104 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 33 | $1,633 | $31 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,534 | $110 |
| Short return visit (20+ min) | 21 | $1,015 | $38 |
| Return visit (30+ min) | 16 | $882 | $49 |
2013: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $8,016 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,856 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,584 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,651 | $83 |
| Return visit (30+ min) | 24 | $2,560 | $85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,736 | $134 |
| Short return visit (20+ min) | 27 | $1,715 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $1,435 | $31 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,282 | $107 |
| Return visit (30+ min) | 13 | $900 | $56 |
| Short return visit (20+ min) | 14 | $815 | $39 |
Medicaid work
$17,633 in 2024
Medicaid paid $17,633 for 264 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 141 | $11,291 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 96 | $3,719 |
| Upper gastrointestinal endoscopy with band ligation of esophageal and gastric varices | 12 | $2,485 |
| Injection, propofol, 10 mg | 15 | $138 |
| 2024 | 264 | 4 | 26 | $17,633 |
| 2023 | 171 | 2 | 17 | $6,165 |
| 2022 | 138 | 2 | 20 | $7,031 |
| 2021 | 168 | 1 | 22 | $8,878 |
| 2020 | 26 | 1 | 13 | $1,087 |
| 2019 | 235 | 2 | 24 | $10,787 |
| 2018 | 586 | 4 | 24 | $28,817 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 111 | $4,346 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 60 | $1,818 |
2022
| Long return visit (40+ min) | 122 | $6,665 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 16 | $366 |
2021
| Long return visit (40+ min) | 168 | $8,878 |
2020
| Long return visit (40+ min) | 26 | $1,087 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 143 | $7,098 |
| Long return visit (40+ min) | 92 | $3,689 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 385 | $18,936 |
| Long return visit (40+ min) | 156 | $7,385 |
| 1ST HOSP IP/OBS HIGH 75 | 29 | $1,852 |
| Return visit (30+ min) | 16 | $644 |
Drugs they prescribed that Part D paid
$565,173
Pharmacies billed $565,173 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
948 generic and 187 brand-name prescriptions · $565,173 in drug cost · 117 antibiotic prescriptions to 33 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 90 | $300,937 | $3,344 |
| Vemlidy | 49 | $68,366 | $1,395 |
| Entecavir | 51 | $5,361 | $105 |
| Tenofovir Disoproxil | 15 | $4,938 | $329 |
| Ursodiol | 53 | $4,438 | $84 |
See all 21 drugs
| Xifaxan | 90 | $300,937 | $3,344 |
| Vemlidy | 49 | $68,366 | $1,395 |
| Entecavir | 51 | $5,361 | $105 |
| Tenofovir Disoproxil | 15 | $4,938 | $329 |
| Ursodiol | 53 | $4,438 | $84 |
| Atovaquone | 13 | $3,654 | $281 |
| Midodrine | 19 | $2,519 | $133 |
| Lactulose | 57 | $1,736 | $30 |
| Mycophenolate Mofetil | 26 | $1,549 | $60 |
| Omeprazole | 123 | $1,478 | $12 |
| Carvedilol | 173 | $1,310 | $8 |
| Tacrolimus | 30 | $656 | $22 |
| Pantoprazole | 62 | $379 | $6 |
| Spironolactone | 45 | $332 | $7 |
| Torsemide | 13 | $291 | $22 |
| Peg 3350-Electrolyte | 13 | $252 | $19 |
| Gabapentin | 13 | $230 | $18 |
| Furosemide | 44 | $126 | $3 |
| Levothyroxine | 11 | $61 | $6 |
| Fludrocortisone Acetate | 11 | $35 | $3 |
| Sertraline | 12 | $31 | $3 |
Year by year
| 2024 | 1,135 | 183 | None | 16% | $565,173 |
| 2023 | 1,051 | 163 | 1% (12) | None | $663,954 |
| 2022 | 752 | 118 | 2% (16) | 22% | $458,369 |
| 2021 | 737 | 103 | 2% (15) | 31% | $669,887 |
| 2020 | 477 | 100 | None | 30% | $316,539 |
| 2019 | 833 | 135 | None | None | $561,927 |
| 2018 | 1,184 | 157 | None | None | $449,566 |
| 2017 | 836 | 118 | None | None | $703,036 |
| 2016 | 755 | 90 | None | None | $1,121,165 |
| 2015 | 611 | 92 | None | None | $1,493,794 |
| 2014 | 414 | 60 | None | None | $398,899 |
| 2013 | 184 | 33 | None | 24% | $37,225 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Xifaxan | 104 | $359,073 | $3,453 |
| Vemlidy | 38 | $56,445 | $1,485 |
| Tacrolimus | 19 | $5,006 | $263 |
| Lactulose | 107 | $4,884 | $46 |
| Tenofovir Disoproxil | 11 | $4,615 | $420 |
| Ursodiol | 48 | $3,506 | $73 |
| Entecavir | 39 | $3,344 | $86 |
| Midodrine | 18 | $1,906 | $106 |
| Carvedilol | 114 | $1,252 | $11 |
| Spironolactone | 73 | $1,228 | $17 |
| Omeprazole | 80 | $966 | $12 |
| Mycophenolate Mofetil | 14 | $664 | $47 |
| Pantoprazole | 46 | $590 | $13 |
| Propranolol | 14 | $493 | $35 |
| Bumetanide | 12 | $433 | $36 |
| Furosemide | 51 | $340 | $7 |
| Peg 3350-Electrolyte | 11 | $248 | $23 |
| Torsemide | 16 | $247 | $15 |
| Levothyroxine | 11 | $150 | $14 |
| Prednisone | 14 | $90 | $6 |
| Sulfamethoxazole-Trimethoprim | 13 | $69 | $5 |
| Famotidine | 12 | $35 | $3 |
2022: 23 drugs
| Xifaxan | 84 | $257,815 | $3,069 |
| Vemlidy | 15 | $20,205 | $1,347 |
| Eliquis | 11 | $7,606 | $691 |
| Ursodiol | 20 | $3,963 | $198 |
| Tacrolimus | 12 | $3,944 | $329 |
| Lactulose | 64 | $2,180 | $34 |
| Entecavir | 21 | $1,989 | $95 |
| Eplerenone | 11 | $1,635 | $149 |
| Potassium Chloride | 15 | $1,052 | $70 |
| Tenofovir Disoproxil | 22 | $977 | $44 |
| Spironolactone | 59 | $800 | $14 |
| Enulose | 16 | $793 | $50 |
| Propranolol | 18 | $743 | $41 |
| Omeprazole | 43 | $616 | $14 |
| Pantoprazole | 47 | $613 | $13 |
| Bumetanide | 12 | $569 | $47 |
| Carvedilol | 46 | $522 | $11 |
| Ciprofloxacin | 22 | $267 | $12 |
| Peg 3350-Electrolyte | 12 | $215 | $18 |
| Furosemide | 24 | $138 | $6 |
| Torsemide | 11 | $127 | $12 |
| Sulfamethoxazole-Trimethoprim | 16 | $104 | $7 |
| Oxycodone-Acetaminophen | 11 | $47 | $4 |
2021: 18 drugs
| Epclusa | 13 | $343,483 | $26,422 |
| Xifaxan | 92 | $262,555 | $2,854 |
| Vemlidy | 26 | $33,412 | $1,285 |
| Ursodiol | 40 | $6,163 | $154 |
| Tenofovir Disoproxil | 49 | $3,195 | $65 |
| Lactulose | 31 | $1,557 | $50 |
| Spironolactone | 64 | $1,122 | $18 |
| Entecavir | 19 | $1,102 | $58 |
| Propranolol | 32 | $776 | $24 |
| Azathioprine | 14 | $708 | $51 |
| Omeprazole | 54 | $494 | $9 |
| Furosemide | 64 | $392 | $6 |
| Ciprofloxacin | 18 | $345 | $19 |
| Pantoprazole | 27 | $316 | $12 |
| Sucralfate | 23 | $286 | $12 |
| Prednisone | 19 | $219 | $12 |
| Torsemide | 15 | $205 | $14 |
| Oxycodone-Acetaminophen | 13 | $46 | $4 |
2020: 13 drugs
| Xifaxan | 71 | $177,561 | $2,501 |
| Vemlidy | 22 | $27,010 | $1,228 |
| Tenofovir Disoproxil | 26 | $4,647 | $179 |
| Entecavir | 15 | $4,536 | $302 |
| Ursodiol | 17 | $4,113 | $242 |
| Lactulose | 26 | $968 | $37 |
| Spironolactone | 46 | $845 | $18 |
| Propranolol | 28 | $505 | $18 |
| Furosemide | 48 | $289 | $6 |
| Pantoprazole | 14 | $228 | $16 |
| Constulose | 11 | $224 | $20 |
| Prednisone | 16 | $215 | $13 |
| Omeprazole | 19 | $73 | $4 |
2019: 23 drugs
| Xifaxan | 94 | $243,840 | $2,594 |
| Truvada | 20 | $34,845 | $1,742 |
| Ursodiol | 28 | $10,398 | $371 |
| Entecavir | 17 | $8,120 | $478 |
| Mycophenolate Mofetil | 22 | $3,597 | $163 |
| Cyclosporine Modified | 17 | $3,325 | $196 |
| Tacrolimus | 45 | $3,194 | $71 |
| Tenofovir Disoproxil | 13 | $2,757 | $212 |
| Nadolol | 28 | $1,679 | $60 |
| Omeprazole | 85 | $1,144 | $13 |
| Lactulose | 25 | $1,108 | $44 |
| Spironolactone | 53 | $578 | $11 |
| Amiloride | 12 | $422 | $35 |
| Torsemide | 13 | $342 | $26 |
| Ciprofloxacin | 17 | $308 | $18 |
| Prednisone | 35 | $307 | $9 |
| Pantoprazole | 17 | $262 | $15 |
| Gavilyte-G | 16 | $202 | $13 |
| Atorvastatin | 16 | $177 | $11 |
| Sulfamethoxazole-Trimethoprim | 19 | $155 | $8 |
| Furosemide | 29 | $110 | $4 |
| Lorazepam | 16 | $80 | $5 |
| Amlodipine Besylate | 17 | $76 | $4 |
2018: 31 drugs
| Xifaxan | 70 | $177,695 | $2,538 |
| Truvada | 12 | $20,403 | $1,700 |
| Vemlidy | 16 | $17,287 | $1,080 |
| Ursodiol | 53 | $16,946 | $320 |
| Tacrolimus | 58 | $8,718 | $150 |
| Entecavir | 19 | $6,248 | $329 |
| Nadolol | 81 | $6,095 | $75 |
| Mycophenolate Mofetil | 57 | $5,162 | $91 |
| Esomeprazole Magnesium | 11 | $3,601 | $327 |
| Cyclosporine Modified | 18 | $3,421 | $190 |
| Spironolactone | 68 | $1,116 | $16 |
| Ciprofloxacin | 32 | $1,081 | $34 |
| Lactulose | 26 | $1,011 | $39 |
| Omeprazole | 98 | $904 | $9 |
| Generlac | 11 | $476 | $43 |
| Pantoprazole | 28 | $454 | $16 |
| Torsemide | 26 | $454 | $17 |
| Chlorthalidone | 12 | $396 | $33 |
| Gavilyte-G | 22 | $346 | $16 |
| Sulfamethoxazole-Trimethoprim | 37 | $305 | $8 |
| Metoprolol | 21 | $243 | $12 |
| Furosemide | 55 | $204 | $4 |
| Prednisone | 32 | $193 | $6 |
| Amlodipine Besylate | 27 | $186 | $7 |
| Ondansetron | 11 | $144 | $13 |
| Gabapentin | 11 | $97 | $9 |
| Atorvastatin | 13 | $82 | $6 |
| Famotidine | 13 | $76 | $6 |
| Metoprolol | 14 | $62 | $4 |
| Lisinopril | 17 | $35 | $2 |
| Trazodone | 12 | $28 | $2 |
2017: 21 drugs
| Xifaxan | 71 | $155,597 | $2,192 |
| Ursodiol | 52 | $19,729 | $379 |
| Vemlidy | 15 | $14,896 | $993 |
| Entecavir | 25 | $13,196 | $528 |
| Tacrolimus | 33 | $7,320 | $222 |
| Lamivudine Hbv | 11 | $4,806 | $437 |
| Colestipol | 12 | $4,312 | $359 |
| Mycophenolate Mofetil | 23 | $3,354 | $146 |
| Nadolol | 50 | $3,269 | $65 |
| Cyclosporine Modified | 11 | $1,755 | $160 |
| Spironolactone | 60 | $1,232 | $21 |
| Omeprazole | 108 | $688 | $6 |
| Ciprofloxacin | 22 | $554 | $25 |
| Propranolol | 13 | $212 | $16 |
| Gavilyte-G | 14 | $182 | $13 |
| Pantoprazole | 16 | $162 | $10 |
| Sulfamethoxazole-Trimethoprim | 13 | $137 | $11 |
| Furosemide | 55 | $126 | $2 |
| Amlodipine Besylate | 12 | $80 | $7 |
| Lisinopril | 19 | $71 | $4 |
| Gabapentin | 11 | $68 | $6 |
2016: 22 drugs
| Harvoni | 28 | $893,932 | $31,926 |
| Xifaxan | 39 | $73,667 | $1,889 |
| Entecavir | 25 | $21,714 | $869 |
| Ursodiol | 15 | $8,912 | $594 |
| Nadolol | 49 | $2,735 | $56 |
| Tacrolimus | 38 | $2,334 | $61 |
| Ribasphere | 11 | $2,266 | $206 |
| Sirolimus | 11 | $2,147 | $195 |
| Omeprazole | 70 | $958 | $14 |
| Mycophenolate Mofetil | 16 | $911 | $57 |
| Spironolactone | 57 | $743 | $13 |
| Azathioprine | 11 | $596 | $54 |
| Metoprolol | 13 | $245 | $19 |
| Sulfamethoxazole-Trimethoprim | 26 | $244 | $9 |
| Propranolol | 12 | $235 | $20 |
| Amlodipine Besylate | 32 | $211 | $7 |
| Fenofibrate | 13 | $178 | $14 |
| Nortriptyline | 12 | $123 | $10 |
| Pantoprazole | 13 | $122 | $9 |
| Furosemide | 46 | $119 | $3 |
| Prednisone | 14 | $99 | $7 |
| Lisinopril | 14 | $91 | $6 |
2015: 17 drugs
| Harvoni | 37 | $1,175,986 | $31,783 |
| Xifaxan | 46 | $74,335 | $1,616 |
| Ursodiol | 20 | $13,795 | $690 |
| Viread | 12 | $11,262 | $939 |
| Ribavirin | 11 | $3,173 | $288 |
| Nadolol | 46 | $2,666 | $58 |
| Tacrolimus | 35 | $2,547 | $73 |
| Omeprazole | 68 | $822 | $12 |
| Lactulose | 21 | $661 | $31 |
| Spironolactone | 24 | $564 | $24 |
| Mycophenolate Mofetil | 12 | $523 | $44 |
| Metoprolol | 12 | $253 | $21 |
| Torsemide | 12 | $180 | $15 |
| Sulfamethoxazole-Trimethoprim | 13 | $96 | $7 |
| Amlodipine Besylate | 14 | $78 | $6 |
| Fenofibrate | 12 | $71 | $6 |
| Lisinopril | 12 | $40 | $3 |
2014: 8 drugs
| Xifaxan | 33 | $50,420 | $1,528 |
| Nadolol | 29 | $2,803 | $97 |
| Tacrolimus | 15 | $2,161 | $144 |
| Omeprazole | 47 | $625 | $13 |
| Spironolactone | 31 | $555 | $18 |
| Lactulose | 11 | $352 | $32 |
| Warfarin | 14 | $126 | $9 |
| Sulfamethoxazole-Trimethoprim | 14 | $120 | $9 |
2013: 5 drugs
| Xifaxan | 21 | $28,097 | $1,338 |
| Spironolactone | 12 | $359 | $30 |
| Omeprazole | 17 | $239 | $14 |
| Sulfamethoxazole-Trimethoprim | 15 | $132 | $9 |
| Amlodipine Besylate | 12 | $82 | $7 |
Money from drug and device companies
$55 in 2025
| 2025 | 1 | 1 | None | $55 |
| 2024 | 2 | 7 | $2,148 | $2,894 |
| 2023 | 1 | 1 | None | $71 |
| 2021 | 1 | 1 | $2,700 | $2,700 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | None | $55 | 1 payment
|
See the published payment
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-21 | None | $55 |
See earlier years (2024, 2023, 2021)
2024: $2,894
| AstraZeneca Pharmaceuticals LP | Imfinzi | $2,373 | 4 payments
|
| Genentech USA | Tecentriq | $521 | 3 payments
|
2023: $71
| Eisai | None | $71 | 1 payment
|
2021: $2,700
| Eisai | Lenvima | $2,700 | 1 payment
|
Professional record
- NPI
- 1871741769
- Licence
- CA C156903, MA 236193California C156903: Current · expires 2028-07-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RT0003X (207RT0003X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RH0002X (207RH0002X); Federal specialty code 207RI0008X (207RI0008X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-09-04
- NPI last updated
- 2025-02-25
- NPI record certified
- 2025-02-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 110 Francis Street, Boston, MA, 02215